Curis Inc - Company Profile

All the sales intelligence you need on Curis Inc in one solution.

Save hours of research time with a comprehensive
Sales Intelligence Solution.
Understand how Curis Inc fits into your total
addressable market and Ideal Customer Profile.
Gain competitive edge with triggers that tell you
when and how to engage with Curis Inc.

Curis Inc: Premium Databases

Contact the team or request a demo to find out how our data can drive your business forward

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

Headline	Published	Journalists
Showing 3 of 5 results.
Deserunt mollit sunt Lorem laborum do id aliqua dolore	30 Apr 2015	Lorem
Novartis’ basal cell carcinoma drug sonidegib elicits cautious optimism for EU approval – experts	29 Apr 2015	Sony Salzman
Curis's Erivedge has potential in operable BCC, but success too early to call - experts	28 Jan 2013	Kotaro Yoshida
Curis’ BCC drug Erivedge expected to gain EMA approval, but surgeon advice before treatment likely - experts	25 Jan 2013	Kotaro Yoshida

Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.

Drug Insights:

Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
Material intelligence on competitors, including breaking news
Insight on companies’ business development needs and strategies

Outsourcing Insights:

Insight on companies’ CRO and business development needs, strategies and relationships

Remove risk and uncertainty

Gain a competitive edge

Secure actionable leads

Gain a 360-degree view of Curis Inc and make more informed decisions for your business

Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer